Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Thibault

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Journal of Clinical Investigation|August 16, 2011
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunityEmilie Mamessier, Aude Sylvain, Marie-Laure Thibult, et al.
Antibodies (Basel, Switzerland)|August 23, 2022
Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro FunctionalityNicolas Aubrey, Valérie Gouilleux-Gruart, Christine Dhommée, et al.
Frontiers in Immunology|May 8, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancerEmilia Rabia, Véronique Garambois, Christine Dhommée, et al.
The Lancet. Oncology|December 3, 2014
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trialBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 22, 2020
The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients - a retrospective studyPhilippe Gatault, Laurie Lajoie, Jana Stojanova, et al.
Eclinicalmedicine|November 18, 2020
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher studyBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 19, 2016
Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donorsCatherine Forconi, Philippe Gatault, Elodie Miquelestorena-Standley, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of Clinical Investigation|August 16, 2011
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunityEmilie Mamessier, Aude Sylvain, Marie-Laure Thibult, et al.
Antibodies (Basel, Switzerland)|August 23, 2022
Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro FunctionalityNicolas Aubrey, Valérie Gouilleux-Gruart, Christine Dhommée, et al.
Frontiers in Immunology|May 8, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancerEmilia Rabia, Véronique Garambois, Christine Dhommée, et al.
The Lancet. Oncology|December 3, 2014
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trialBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 22, 2020
The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients - a retrospective studyPhilippe Gatault, Laurie Lajoie, Jana Stojanova, et al.
Eclinicalmedicine|November 18, 2020
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher studyBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 19, 2016
Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donorsCatherine Forconi, Philippe Gatault, Elodie Miquelestorena-Standley, et al.
Pageof 4